+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
Healthy Volunteers
ID06952517

Study of Clascoterone Cream 1% for Treating Facial Acneiform Rosacea in Adults

Led by Narrows Institute for Biomedical Research · Updated on 2025-05-06

20

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of Clascoterone cream 1% in reducing the size of sebaceous glands in adults with acneiform rosacea, specifically papulopustular rosacea. This Phase 2 study aims to assess both the treatments impact on gland size and its safety profile during a 12-week treatment period. Participants will use Clascoterone 1% cream topically on affected facial areas. The study includes adults diagnosed with papulopustular rosacea who apply the cream regularly for 12 weeks. There is no placebo group or masking in this trial. During the study, researchers will perform biopsies to measure sebaceous gland size before and after treatment. They will also take digital photographs to document clinical changes, and collect both physician and participant assessments. Safety and any adverse events will be monitored throughout the 12-week period to evaluate the overall effects of the cream.

CONDITIONS

Brief Title

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

Research Team

K

Kayla N Zafar, BA

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here